美敦力（MDT）今日盘前股价大涨5.55%，引起了市场的广泛关注。
消息面上，美敦力公布了2026财年第四季度及全年业绩，其营收与调整后利润均超出华尔街分析师预期，并实现了过去十年以来最强劲的年度营收增长。具体来看，第四财季营收达98.1亿美元，高于市场预期的96.3亿美元，其中核心心血管业务销售额受脉冲场消融（PFA）产品组合的旺盛需求推动，同比大幅增长13.8%。
与此同时，公司宣布了一系列战略举措以强化未来增长动能，包括对Beluga Medica等公司进行投资以获取先进心脏成像导管技术、支持心脏消融产品组合的扩张，以及提交了将其Hugo™机器人手术系统应用拓展至普外科及妇科领域的510(K)申请。这些新产品管线的加速落地与积极的业务拓展，进一步提振了市场对该公司长期发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.